Search

Displaying results 4321 - 4330 of 10000 in total
  1. Drug

    Sulfaloxic acid

    go.drugbank.com/drugs/DB19971
    Experimental

    Sulfaloxic acid has a monoisotopic molecular weight of 393.06 Da.

  2. Drug

    Sorbitan monopalmitate

    go.drugbank.com/drugs/DB20199
    Experimental

    Sorbitan monopalmitate has a monoisotopic molecular weight of 402.3 Da.

  3. Drug

    Napsagatran anhydrous

    go.drugbank.com/drugs/DB20288
    Experimental

    Napsagatran anhydrous has a monoisotopic molecular weight of 558.23 Da.

  4. Drug

    Olpadronic acid

    go.drugbank.com/drugs/DB20303
    Investigational

    Olpadronic acid has a monoisotopic molecular weight of 263.03 Da.

  5. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy.

  6. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    [A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717] … [L44717] Anacaulase is indicated for eschar removal in patients with deep partial thickness and/or full-thickness thermal burns.

  7. Drug

    Tebipenem pivoxil

    go.drugbank.com/drugs/DB16840
    Approved

    [L57980] Tebipenem pivoxil is the first oral carbapenem approved in the United States, creating an outpatient option for patients who have limited or no alternative oral therapy. … [L57979] The FDA approved tebipenem pivoxil on June 17, 2026, for complicated urinary tract infections including pyelonephritis caused by designated susceptible organisms in adult patients who have

  8. Drug

    Crovalimab

    go.drugbank.com/drugs/DB16128
    ApprovedInvestigational

    [A263958] It soon gained its approval in Japan in the next month,[A263958] and in the USA in June of the same year. … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

  9. Drug

    Oglufanide

    go.drugbank.com/drugs/DB05779
    Investigational

    Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before … being acquired by Implicit Bioscience in 2005.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Cod liver oil

    go.drugbank.com/drugs/DB11321
    ApprovedNutraceuticalVet approved

    Also being a rich source of vitamin A and D, cod liver oil can be taken orally as daily supplements. … It is used as an adjunct treatment and preventative therapy of rickets, osteomalacia and osteoporosis while meeting the consumption criteria.